SARS-CoV-2 Vaccination Rates and Uptake of Tixagevimab-Cilgavimab Among a Cohort of Pediatric Solid Organ Transplant Recipients

IF 1.9 4区医学 Q2 SURGERY

Clinical Transplantation Pub Date : 2024-07-21 DOI:10.1111/ctr.15407

Christopher A. Reis, Elizabeth H. Ristagno, Theresa Madigan

{"title":"SARS-CoV-2 Vaccination Rates and Uptake of Tixagevimab-Cilgavimab Among a Cohort of Pediatric Solid Organ Transplant Recipients","authors":"Christopher A. Reis, Elizabeth H. Ristagno, Theresa Madigan","doi":"10.1111/ctr.15407","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>There is a lack of data regarding SARS-CoV-2 vaccination rates and tixagevimab-cilgavimab (TC) uptake among pediatric solid organ transplant recipients. The purpose of our study was to assess these rates.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>We reviewed vaccination records of pediatric recipients of heart, kidney, and liver transplants at Mayo Clinic, Rochester, MN, who received a transplant between January 2011 and December 2021. All SARS-CoV-2 vaccines and doses of TC received on or before September 1, 2022, the date of approval of the bivalent SARS-CoV2 vaccine, were included. We also assessed whether patients had been seen by an infectious diseases physician (ID) in the preceding 6 months.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Our study included 110 patients: 47 kidney, 36 heart, and 27 liver transplant recipients. All vaccine doses recorded were monovalent SARS-CoV-2 vaccines. Sixty-eight (61.8%) patients received at least one vaccine. This varied by age group, with f of ≥12 years olds, 40.9% of 5–11 year olds and 14.3% of under 5 year olds (<i>p</i> = 0.001). Seven patients (6.4%) were up-to-date (UTD) for age. There was no difference in UTD status by organ type (<i>p</i> = 0.335). Patients who saw ID were significantly more likely to be UTD (13.2% versus 2.8%; <i>p</i> = 0.047). Among those eligible, 14 (18.2%) received TC, with rates not different based on transplanted organ type (<i>p</i> = 0.158) or whether they saw ID (<i>p</i> = 0.273).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Despite the availability of vaccines, nearly 40% of pediatric solid organ transplant recipients remained unvaccinated against SARS-CoV-2 at time of the bivalent vaccine release. Less than a fifth of eligible patients received TC. Strategies to increase uptake of SARS-CoV-2 vaccines as well as adjunctive agents among this vulnerable group should be further explored.</p>\n </section>\n </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ctr.15407","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

There is a lack of data regarding SARS-CoV-2 vaccination rates and tixagevimab-cilgavimab (TC) uptake among pediatric solid organ transplant recipients. The purpose of our study was to assess these rates.

Materials and Methods

We reviewed vaccination records of pediatric recipients of heart, kidney, and liver transplants at Mayo Clinic, Rochester, MN, who received a transplant between January 2011 and December 2021. All SARS-CoV-2 vaccines and doses of TC received on or before September 1, 2022, the date of approval of the bivalent SARS-CoV2 vaccine, were included. We also assessed whether patients had been seen by an infectious diseases physician (ID) in the preceding 6 months.

Results

Our study included 110 patients: 47 kidney, 36 heart, and 27 liver transplant recipients. All vaccine doses recorded were monovalent SARS-CoV-2 vaccines. Sixty-eight (61.8%) patients received at least one vaccine. This varied by age group, with f of ≥12 years olds, 40.9% of 5–11 year olds and 14.3% of under 5 year olds (p = 0.001). Seven patients (6.4%) were up-to-date (UTD) for age. There was no difference in UTD status by organ type (p = 0.335). Patients who saw ID were significantly more likely to be UTD (13.2% versus 2.8%; p = 0.047). Among those eligible, 14 (18.2%) received TC, with rates not different based on transplanted organ type (p = 0.158) or whether they saw ID (p = 0.273).

Conclusions

Despite the availability of vaccines, nearly 40% of pediatric solid organ transplant recipients remained unvaccinated against SARS-CoV-2 at time of the bivalent vaccine release. Less than a fifth of eligible patients received TC. Strategies to increase uptake of SARS-CoV-2 vaccines as well as adjunctive agents among this vulnerable group should be further explored.

查看原文本刊更多论文

儿科实体器官移植受者队列中的 SARS-CoV-2 疫苗接种率和 Tixagevimab-Cilgavimab 使用率。

导言：关于小儿实体器官移植受者的 SARS-CoV-2 疫苗接种率和替沙单抗-西格维单抗 (TC) 使用率，目前还缺乏相关数据。我们的研究旨在评估这些接种率：我们查阅了明尼苏达州罗切斯特梅奥诊所在 2011 年 1 月至 2021 年 12 月期间接受心脏、肾脏和肝脏移植的儿科受者的疫苗接种记录。所有在 2022 年 9 月 1 日（二价 SARS-CoV2 疫苗获得批准的日期）或之前接种的 SARS-CoV-2 疫苗和 TC 剂量均包括在内。我们还评估了患者在前 6 个月是否接受过传染病医生（ID）的诊治：我们的研究共纳入 110 名患者：结果：我们的研究包括 110 名患者：47 名肾移植受者、36 名心脏移植受者和 27 名肝移植受者。所有记录的疫苗剂量均为单价 SARS-CoV-2 疫苗。68名患者（61.8%）至少接种了一种疫苗。各年龄组的情况有所不同，≥12 岁的患者接种了 f，5-11 岁的患者接种了 40.9%，5 岁以下的患者接种了 14.3%（p = 0.001）。有 7 名患者（6.4%）的年龄符合要求（UTD）。不同器官类型的UTD状况没有差异（p = 0.335）。看 ID 的患者UTD 的可能性明显更高（13.2% 对 2.8%；p = 0.047）。在符合条件的患者中，有14人（18.2%）接受了TC治疗，根据移植器官类型（p = 0.158）或是否看过ID（p = 0.273），接受TC治疗的比例没有差异：结论：尽管疫苗已经上市，但在二价疫苗上市时，仍有近 40% 的小儿实体器官移植受者未接种 SARS-CoV-2 疫苗。只有不到五分之一的符合条件的患者接种了 TC。应进一步探索提高这一易感人群对SARS-CoV-2疫苗和辅助药物接受率的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Transplantation 医学-外科

CiteScore

3.70

自引率

4.80%

发文量

286

审稿时长

2 months

期刊介绍： Clinical Transplantation: The Journal of Clinical and Translational Research aims to serve as a channel of rapid communication for all those involved in the care of patients who require, or have had, organ or tissue transplants, including: kidney, intestine, liver, pancreas, islets, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored. Published monthly, Clinical Transplantation’s scope is focused on the complete spectrum of present transplant therapies, as well as also those that are experimental or may become possible in future. Topics include: Immunology and immunosuppression; Patient preparation; Social, ethical, and psychological issues; Complications, short- and long-term results; Artificial organs; Donation and preservation of organ and tissue; Translational studies; Advances in tissue typing; Updates on transplant pathology;. Clinical and translational studies are particularly welcome, as well as focused reviews. Full-length papers and short communications are invited. Clinical reviews are encouraged, as well as seminal papers in basic science which might lead to immediate clinical application. Prominence is regularly given to the results of cooperative surveys conducted by the organ and tissue transplant registries. Clinical Transplantation: The Journal of Clinical and Translational Research is essential reading for clinicians and researchers in the diverse field of transplantation: surgeons; clinical immunologists; cryobiologists; hematologists; gastroenterologists; hepatologists; pulmonologists; nephrologists; cardiologists; and endocrinologists. It will also be of interest to sociologists, psychologists, research workers, and to all health professionals whose combined efforts will improve the prognosis of transplant recipients.